Julie & Holleman LLP is investigating whether Personalis shareholders are receiving fair value in Tempus AI's proposed acquisition at $16.25 per share. Tempus, already a significant shareholder and strategic partner since 2023, may have conflicts of interest affecting the sale process. The law firm questions if the offer reflects Personalis' long-term value, especially given its leadership in the growing molecular residual disease testing market. Shareholders are encouraged to seek legal advice regarding potential claims.
Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal...
Tempus AI will acquire Personalis in a $1.5 billion all-stock deal, expanding its cancer recurrence monitoring capabilities. Personalis shareholders will receive $16.25 per share, a premium of 6% over the recent closing price. The acquisition builds ...
